Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HBIO
stocks logo

HBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
23.10M
-5.93%
0.005
-125%
21.25M
-2.41%
0.035
-41.67%
22.75M
+11.25%
-0.005
-50%
Estimates Revision
The market is revising Upward the revenue expectations for Harvard Bioscience, Inc. (HBIO) for FY2025, with the revenue forecasts being adjusted by 0.7% over the past three months. During the same period, the stock price has changed by 51.17%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.7%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+20%
In Past 3 Month
Stock Price
Go Up
up Image
+51.17%
In Past 3 Month
Wall Street analysts forecast HBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HBIO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HBIO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.723
sliders
Low
2.00
Averages
2.00
High
2.00
Current: 0.723
sliders
Low
2.00
Averages
2.00
High
2.00
Benchmark
Bruce Jackson
Speculative Buy
downgrade
$3 -> $2
2025-09-10
Reason
Benchmark
Bruce Jackson
Price Target
$3 -> $2
2025-09-10
downgrade
Speculative Buy
Reason
Benchmark analyst Bruce Jackson lowered the firm's price target on Harvard Bioscience to $2 from $3 and keeps a Speculative Buy rating on the shares. Concerns about basic research funding, drug pricing, and tariffs create an uncertain environment for the sector that seems likely to persist for the near future, says the analyst, who cites the heightened risk profile for the firm's lowered target.
Benchmark
Speculative Buy
downgrade
$3
2025-05-13
Reason
Benchmark
Price Target
$3
2025-05-13
downgrade
Speculative Buy
Reason
Benchmark lowered the firm's price target on Harvard Bioscience to $3 from $4.50 and keeps a Speculative Buy rating on the shares. The outlook for end-user markets in biomedical research continues to be challenging due to uncertainty around China tariffs, NIH funding, and biopharmaceutical research activity, which leads the firm to lower its 2025 revenue estimate as a result. However, despite the near-term uncertainty, management remains optimistic about the 2025 prospects for newly launched products, says the analyst, who believes shares could experience multiple expansion if the company continues to execute its plan to grow the business organically, increase cash flow, and pay down debt.
Keybanc
Paul Knight
Buy
to
Hold
Downgrades
n/a
2025-04-09
Reason
Keybanc
Paul Knight
Price Target
n/a
2025-04-09
Downgrades
Buy
to
Hold
Reason
KeyBanc downgraded Harvard Bioscience to Sector Weight from Overweight.
Benchmark
Bruce Jackson
Buy
Maintains
$5.5 → $4.5
2025-03-24
Reason
Benchmark
Bruce Jackson
Price Target
$5.5 → $4.5
2025-03-24
Maintains
Buy
Reason
Benchmark lowered the firm's price target on Harvard Bioscience to $4.50 from $5.50 and keeps a Speculative Buy rating on the shares. End-user markets in biomedical research continue to be challenging for Harvard, says the analyst, who is lowering estimates as a result.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Harvard Bioscience Inc (HBIO.O) is 8.50, compared to its 5-year average forward P/E of 23.63. For a more detailed relative valuation and DCF analysis to assess Harvard Bioscience Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
23.63
Current PE
8.50
Overvalued PE
42.74
Undervalued PE
4.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.22
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
20.20
Undervalued EV/EBITDA
8.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.41
Current PS
0.00
Overvalued PS
2.13
Undervalued PS
0.69
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HBIO News & Events

Events Timeline

(ET)
2025-11-06
07:05:24
Harvard Bioscience Projects Q4 Revenue Between $22.5M and $24.5M
select
2025-11-06
07:05:00
Harvard Bioscience announces Q3 adjusted EPS of 0 cents compared to a loss of 2 cents in the previous year.
select
2025-09-16 (ET)
2025-09-16
07:04:56
Harvard Bioscience broadens partnership with Fisher Scientific for distribution.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-18CNBC
Larry Summers Withdraws from Public Engagements Amid Email Controversy in Jeffrey Epstein Files

  • Larry Summers Steps Back: Former Treasury Secretary Larry Summers announced he is stepping back from public commitments due to the fallout from emails with Jeffrey Epstein, expressing deep shame and taking full responsibility for his actions.

  • Details of the Emails: The emails revealed Summers sought advice from Epstein regarding a romantic interest while he was married, raising concerns about his judgment and relationships.

  • Calls for Action: Senator Elizabeth Warren criticized Summers, stating that Harvard should sever ties with him, arguing that his association with Epstein demonstrates a lack of trustworthiness, especially in an educational context.

  • Context of Epstein's Crimes: The controversy comes in the wake of Epstein's arrest and subsequent death in 2019, following serious charges related to child sex trafficking.

[object Object]
Preview
8.0
10-13CNBC
Experts advise on ways to safeguard children as they increasingly rely on AI chatbots for critical thinking.

  • AI Usage Among Youth: A significant increase in U.S. teens using AI tools like ChatGPT for schoolwork has been observed, with 26% reporting usage in 2024, prompting regulatory scrutiny and the introduction of parental controls by OpenAI.

  • Cognitive Risks of AI: Research indicates that reliance on AI chatbots may diminish critical thinking and creativity in young users, with concerns about cognitive debt and the potential for negative developmental impacts, particularly for children.

  • Need for Skills and Literacy: Experts emphasize the importance of teaching children foundational skills and computer literacy before they engage with AI tools, to help them navigate inaccuracies and develop critical thinking.

  • Parental Guidance and Monitoring: Parents are encouraged to maintain open communication with their children regarding AI usage and to monitor the tools they interact with, ensuring responsible and safe engagement with technology.

[object Object]
Preview
7.0
09-04CNBC
Judge overturns Trump administration's $2.2 billion funding freeze for Harvard

  • Court Ruling on Funding Freeze: A federal judge ruled that the Trump administration's $2.2 billion funding freeze for Harvard University was illegal, stating it was imposed in retaliation for the university's refusal to comply with unconstitutional demands.

  • Concerns Over Antisemitism: The judge found that the administration's focus on antisemitism was arbitrary and pretextual, as the funding freeze occurred before any investigation into antisemitism on campus and was linked to broader ideological concerns.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Harvard Bioscience Inc (HBIO) stock price today?

The current price of HBIO is 0.7229 USD — it has decreased -0.69 % in the last trading day.

arrow icon

What is Harvard Bioscience Inc (HBIO)'s business?

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

arrow icon

What is the price predicton of HBIO Stock?

Wall Street analysts forecast HBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HBIO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Harvard Bioscience Inc (HBIO)'s revenue for the last quarter?

Harvard Bioscience Inc revenue for the last quarter amounts to 20.59M USD, decreased -6.27 % YoY.

arrow icon

What is Harvard Bioscience Inc (HBIO)'s earnings per share (EPS) for the last quarter?

Harvard Bioscience Inc. EPS for the last quarter amounts to -0.03 USD, decreased -72.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Harvard Bioscience Inc (HBIO)'s fundamentals?

The market is revising Upward the revenue expectations for Harvard Bioscience, Inc. (HBIO) for FY2025, with the revenue forecasts being adjusted by 0.7% over the past three months. During the same period, the stock price has changed by 51.17%.
arrow icon

How many employees does Harvard Bioscience Inc (HBIO). have?

Harvard Bioscience Inc (HBIO) has 330 emplpoyees as of December 05 2025.

arrow icon

What is Harvard Bioscience Inc (HBIO) market cap?

Today HBIO has the market capitalization of 32.23M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free